🔭 Futures
← All gates

FDA or equivalent authority approves a drug (or therapy) that halts or reverses biological aging in humans

draft conf: low
healthcare labor family housing
Trigger
The FDA, EMA, or another major regulatory authority (PMDA, NMPA) grants marketing approval — full or accelerated — to a drug or biological therapy whose labeled indication explicitly includes halting or reversing biological aging (as measured by a validated biomarker such as epigenetic age, DunedinPACE, or a composite aging endpoint), or whose Phase III/pivotal trial demonstrated statistically significant reduction in all-cause mortality or multi-morbidity incidence attributable to aging biology rather than a single disease.
Timeline
2027
2030
2033
2036
2040
2045
2050
P10 2037
P50 2048
P90 → 2072
42 sources last updated: 2026-05-27 View raw .md ↗
Prediction history
1 entry · latest first
  1. 2026-05-27
    P10 2037 · P50 2048 · P90 2072
    Initial estimate from initial research.
Cross-gate links
enables [strong] ai-agent-30pct-knowledge-work correlates [medium] global-economy-explosive-growth correlates [weak] humanoid-10m-households correlates [weak] ai-tutor-k8-parity-20mo correlates [weak] cell-meat-beef-parity substitutes [medium] brain-in-vat-body-replacement
Key dependencies — watch these
  • §
    FDA aging-as-indication regulatory pathway accelerates
    Without formal FDA/EMA recognition of aging as an approvable indication, the gate trigger cannot technically be met regardless of clinical evidence; establishment of this pathway (P50 2033) is the single most binding non-scientific prerequisite.
  • ⊞
    AI handling 30%+ of knowledge work by 2028 compresses the drug discovery cycle by 3-5 years and shifts this gate's P10 from 2040 to 2037, making it the strongest identified accelerant.
  • ▲
    Partial reprogramming cancer safety signals delays
    A single teratoma or oncogenic event in the ER-100 or equivalent Phase I/II trial could set the entire reprogramming field back a decade, directly delaying the most promising therapeutic pathway.
  • ≣
    Epigenetic clock validated as surrogate endpoint accelerates
    Formal regulatory validation of DunedinPACE or GrimAge as a surrogate endpoint (P50 2032) is a prerequisite for any aging-specific pivotal trial; without it, multi-year mortality trials become the only option, adding 10-15 years to timelines.
  • ▲
    Mouse-to-human translation failure delays
    If the 30% lifespan extension from rapamycin+trametinib in mice fails to translate to humans — as caloric restriction largely did in primates — the core pharmacological pipeline collapses and P90 extends well beyond 2072.
  • ⊞
    Explosive GDP growth funds the trillion-dollar R&D and deployment costs required for population-scale geroprotection, while aging-halt itself is the single strongest long-run GDP lever (McKinsey: 5-year healthspan extension adds $12T/year); the two gates are mutually reinforcing and roughly co-timed (both P50 ~2048-2049).
  • $
    Longevity biotech funding sustainability both
    The sector has attracted $13B+ with zero approved products; accumulation of high-profile failures (Unity collapse, Calico ALS failure) could trigger investor retreat before science matures, while success in early sub-gates (dog longevity approval, first senolytic approval) could catalyze a funding surge that accelerates all subsequent timelines.

TL;DR

This gate asks when a major regulatory authority will approve a therapy that explicitly halts or reverses biological aging — not just treats one age-related disease, but targets the aging process itself. P50: 2048, P10: 2037, P90: 2072. The field is at an inflection point in May 2026: the first-ever human trial of partial epigenetic reprogramming (Life Biosciences’ ER-100, FDA IND cleared January 2026) is underway; Calico’s IL-11 antibody (22-25% mouse lifespan extension) completed Phase I; rapamycin+trametinib combination showed 30% mouse lifespan extension (Nature Aging, May 2025); and over $13 billion in venture capital has flooded longevity biotech. But the gap between “extends mouse lifespan” and “FDA-approved age-freezing drug” is enormous: no regulatory authority recognizes aging as an approvable indication, no epigenetic clock is validated as a surrogate endpoint, and the most advanced human anti-aging trials are Phase I/II for disease-specific indications (not aging itself). The optimist case (P10 2037) requires AI-accelerated drug discovery to compress timelines by 5-10 years, the TAME trial or equivalent to establish aging-as-indication, and at least one geroprotector to show multi-morbidity reduction in a pivotal trial. The pessimist case (P90 2072) reflects the possibility that aging is too complex for a single drug, regulatory frameworks remain disease-specific for decades, or safety signals (cancer from reprogramming, immunosuppression from rapamycin) constrain deployment. The central estimate (P50 2048) assumes the regulatory pathway opens in the early 2030s, first disease-specific geroprotector approvals come in the mid-2030s, and the accumulated clinical evidence eventually supports an aging-specific indication by the late 2040s.

Current state (as of 2026-05-27)

Funding landscape: Longevity biotech has attracted over $13 billion in cumulative venture funding. 2024-2025 saw a sharp rebound to ~$8.5B annually, with cellular reprogramming capturing 50% of all funding ($1.33B across 6 deals). Top-funded companies: Retro Biosciences ($1.2B, valued at $1.8B as of May 2026), Altos Labs ($3B, Bezos/Milner-backed), NewLimit ($280M, Brian Armstrong), Calico (>$2.5B from Alphabet cumulative). Big pharma entered in 2025: Eli Lilly invested in NewLimit; AbbVie Ventures led Oisin Biotechnologies’ Series A (though AbbVie terminated its Calico collaboration in November 2025 after a Phase II/III ALS trial failure). Unity Biotechnology, once valued at $700M+, is no longer operating — a cautionary tale for the sector [1][2][3].

Most advanced clinical programs (human trials):

  • Life Biosciences ER-100 — First-ever human trial of partial epigenetic reprogramming. FDA IND cleared January 28, 2026. Phase I initiated Q1 2026 for optic neuropathies (glaucoma, NAION). Uses OSK Yamanaka factors (excluding c-Myc to reduce cancer risk). Co-founded by David Sinclair. If successful, provides proof-of-concept for cellular rejuvenation in humans [4][5][6].
  • Retro Biosciences RTR242 — Phase I trial in Australia (8 patients dosed December 2025) for Alzheimer’s disease via enhanced cellular waste clearance. CEO Joe Betts-LaCroix reported “super good” progress with no dose-limiting toxicities; data expected August 2026 [7][8].
  • Calico 9MW3811 (anti-IL-11) — Licensed from Mabwell for $25M upfront + $571M milestones (June 2025). Completed Phase I in Australia and China with favorable safety and >1-month half-life. Extended mouse lifespan 22-25% by reducing cancer, fibrosis, and chronic inflammation. Phase II planning underway [9][10].
  • Insilico Medicine ISM001-055 (rentosertib) — First AI-discovered drug with anti-aging properties. Phase IIa trial (60 patients, US) with primary completion projected February 2026. Showed senomorphic properties — suppresses cellular senescence and SASP [11][12].
  • PEARL Trial (rapamycin) — 48-week human RCT results published April 2025. Low-dose intermittent rapamycin is safe in healthy aging adults; improved lean tissue mass and pain in women (5mg group). However, relied on self-reporting and provided no direct evidence of lifespan extension [13][14].
  • TAME Trial (metformin) — Still not launched as of 2026 due to persistent funding shortfalls. Aims to recruit 3,000 adults aged 65-80 for a 6-year trial of metformin to delay multimorbidity. May be overtaken by events [15].
  • Dasatinib+Quercetin senolytics — Pilot human trials in diabetic kidney disease, Alzheimer’s risk, psychiatric disorders. Reduced senescent cells and inflammation in DKD patients. Still early-phase with small cohorts [16].

Animal model records: The rapamycin+trametinib combination (Nature Aging, May 2025) achieved ~30% median lifespan extension in mice — the largest pharmacological effect from a defined combination to date. Rapamycin alone: 15-20%. Trametinib alone: 5-10%. Anti-IL-11 antibody: 22-25%. Aubrey de Grey’s combination-of-four interventions in middle-aged mice showed additive effects; he plans an eight-intervention combination next [17][18].

Epigenetic clocks and biomarkers: GrimAge, DunedinPACE, and PhenoAge are the most clinically useful clocks in 2026. DunedinPACE measures rate-of-aging rather than static biological age and outperforms telomere length in mortality prediction. However, no epigenetic clock has achieved formal regulatory validation as a surrogate endpoint. The correlation-vs-causation gap remains open: it is unclear whether methylation changes drive or merely accompany aging [19][20].

Regulatory environment: No regulatory authority (FDA, EMA, PMDA, NMPA) currently recognizes aging as an approvable indication. The FDA’s geroscience guidance encourages functional measures (walking speed, fall rates, hospitalizations) rather than biomarker-only endpoints. The PROSPR program aims to develop novel clinical trial designs for gerotherapeutics but remains pre-regulatory. The WHO’s ICD-11 includes code MG2A (“Old age”) but this is not equivalent to recognizing aging as a treatable disease. The field’s regulatory strategy is to first win disease-specific approvals (IPF, DKD, osteoarthritis) that demonstrably target aging biology, then use accumulated evidence to argue for an aging indication [21][22][23].

Dog longevity as leading indicator: Loyal’s LOY-002 has cleared 2 of 3 FDA-CVM technical sections (safety + reasonable expectation of effectiveness). If manufacturing review passes, conditional approval could come late 2026 or 2027 — making it the first drug approved to extend lifespan in any species. The TRIAD trial (rapamycin in ~580 dogs) is underway via the Dog Aging Project [24][25].

AI acceleration: 173+ AI-discovered programs are in clinical development (94 Phase I, 56 Phase II, 15 Phase III). AI-discovered compounds show 80-90% Phase I success rates vs. historical 40-65%. Retro + OpenAI partnership made reprogramming 50x more efficient. Insilico Medicine launched the industry’s first Longevity Board (April 2026) for AI-enabled aging research oversight. Alphabet invests $50B in AI drug discovery via DeepMind, Isomorphic, and Calico [26][27][28].

Supercentenarian context: The oldest verified living person is Ethel Caterham (UK, born August 1909, age 116). The all-time record remains Jeanne Calment at 122 years 164 days. There are 269 validated living supercentenarians. The verified-lifespan ceiling has not meaningfully moved in 30 years — a signal that without intervention, human maximum lifespan may be biologically bounded [29].

Key uncertainties

  1. Is aging a solvable engineering problem or an irreducible biological constraint? Aubrey de Grey says engineering problem (SENS framework). Peter Fedichev says human aging is mostly stochastic and likely irreversible. This is the foundational uncertainty. If Fedichev is right, this gate may never pass. If de Grey is right, P10 could be aggressive.

  2. Will the FDA (or any regulator) create an aging-as-indication pathway? Without this, therapies must be approved disease-by-disease (rapamycin for IPF, senolytics for DKD, etc.), and the gate trigger — approval of an “age-freezing drug” — cannot technically be met. The TAME trial was designed to force this regulatory conversation, but it remains unfunded after 8+ years.

  3. Cancer risk from partial reprogramming. Yamanaka factors are potent oncogenes. Life Biosciences excluded c-Myc, but OCT4 and SOX2 are also associated with tumorigenesis. If Phase I/II safety signals emerge, the entire reprogramming field could be set back by a decade.

  4. Translation gap: mouse-to-human. The 30% lifespan extension from rapamycin+trametinib in mice is extraordinary, but mouse-to-human translation in aging has historically been poor. Caloric restriction extends mouse lifespan by 30-40% but shows modest effects in primates. The species scaling problem is the most understudied bottleneck.

  5. AI-driven acceleration magnitude. If AI compresses drug discovery from 10-15 years to 3-5 years (the optimist case), the P10 could be as early as 2035. If AI helps mainly with target identification but not clinical trials (which are bottlenecked by biology, not computation), the acceleration is modest.

  6. Combination therapy complexity. Aging involves 12+ hallmarks (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, dysbiosis). A single drug targeting one hallmark may be insufficient. A validated combinatorial protocol requires exponentially more clinical testing.

  7. Public acceptance and access. Even if approved, an age-freezing therapy could face political backlash (inequality concerns, population growth, pension system collapse) that limits deployment. Some jurisdictions may refuse to cover or even approve such therapies.

  8. Funding sustainability. The longevity biotech sector has attracted >$13B but has produced zero approved products. If high-profile failures (Unity Biotechnology’s collapse, Calico’s ALS drug failure) accumulate, investor patience may wane before the science matures.

Sub-gate deep dives

FDA aging-as-indication pathway (P50: 2033)

The single most important regulatory prerequisite. Today, the FDA cannot approve a drug “for aging” because aging is not classified as a disease. The closest precedent is the TAME trial design, which proposed measuring time-to-first-occurrence of any age-related chronic disease (cardiovascular, cancer, dementia, mobility decline, cognitive decline, death) as a composite endpoint. This design was reviewed and accepted by the FDA as a valid trial framework, but the trial itself remains unfunded after 8+ years of effort.

The PROSPR program (American Federation for Aging Research) is developing novel clinical trial designs, real-world resilience metrics, and biomarker strategies for gerotherapeutics. If any of the current Phase I/II trials (ER-100, RTR242, 9MW3811) produce strong enough signals, they could catalyze FDA action. The geroscience community expects regulatory clarity by the early 2030s, with P50 2033 reflecting the likely timeline for completing a pivotal aging-endpoint trial + FDA guidance finalization.

Senolytics — drugs that clear senescent cells — are the most conceptually straightforward anti-aging approach and have the most human safety data (dasatinib is FDA-approved for leukemia; quercetin is a dietary supplement). The combination has shown senescent cell clearance in DKD patients. However, the path to approval for an age-related indication requires large Phase III trials, which are expensive and slow. Calico’s 9MW3811 (anti-IL-11) is a stronger candidate: it completed Phase I, showed dramatic mouse lifespan extension, has a well-characterized mechanism, and Calico has deep pockets ($571M in milestones committed). P50 2035 assumes Phase II (2027-2030), Phase III (2030-2034), and FDA review (2034-2035).

Partial reprogramming safe in humans (P50: 2034)

Life Biosciences’ ER-100 Phase I (optic neuropathies, initiated Q1 2026) is the critical test. If safety data are clean by ~2028, Phase II could begin 2029-2030. Altos Labs is reportedly in early human testing as of August 2025. Turn Biotechnologies’ ERA platform is in late preclinical for dermatology and immunology. The cancer risk question is paramount: even a single teratoma in a clinical trial would be a major setback. P50 2034 assumes Phase I safety established by 2028, Phase II efficacy in a tissue-specific indication by 2032, and broader safety confidence by 2034.

Epigenetic clock validated as regulatory endpoint (P50: 2032)

DunedinPACE and GrimAge are the leading candidates. Validation requires demonstrating that a change in epigenetic age predicts a change in hard clinical outcomes (mortality, multi-morbidity) in a prospective trial. The Lancet eBioMedicine review (2026) confirms clocks are “advancing toward clinical use” but notes the correlation-vs-causation gap. P50 2032 assumes at least one completed RCT using an epigenetic clock as a co-primary endpoint by 2030, with 2 years for regulatory review and formal guidance.

Longevity escape velocity (P50: 2057)

LEV — sustained life expectancy increase of >=1 year per year — is the downstream consequence of this gate, not a prerequisite. Metaculus community median: June 2053 (143 forecasters). Requires not just one approved drug but a combinatorial therapy stack deployed at population scale. P50 2057 reflects the lag between first approval (P50 2048 for this gate) and population-scale deployment + accumulated evidence that the therapy actually extends life expectancy at the population level.

Life expectancy crosses 100 in OECD country (P50: 2065)

Current highest life expectancy: Monaco 86.5 years. Historical improvement rate: ~2.5 years/decade in top countries. Without breakthrough therapies, 100 is not reachable until 2090+. With successful geroprotector deployment starting in the 2040s-2050s, the curve accelerates. P50 2065 assumes therapies approved in the late 2040s take 15-20 years to bend the population curve enough.

Cross-gate interactions

AI agent 30% knowledge work (P50 2029) —> This gate: ENABLES, STRONG. AI is already the leading accelerant for longevity drug discovery. The Retro+OpenAI partnership made cellular reprogramming 50x more efficient. Insilico Medicine’s ISM001-055 went from AI target discovery to Phase IIa in under 4 years — a timeline that would have been 8-12 years conventionally. If AI agents handle 30%+ of knowledge work by 2029, the drug discovery cycle compresses further: literature synthesis, target identification, molecular design, clinical trial optimization, and regulatory submission preparation are all knowledge-work tasks. This is the most important cross-gate interaction: it shifts the P10 of this gate from 2040 to 2037.

Global economy explosive growth (P50 2049) <—> This gate: CORRELATES, MEDIUM. Bidirectional interaction. If aging is halted, the dependency ratio inverts (no retirement wave), human capital compounds over centuries, and GDP growth accelerates — potentially contributing to explosive growth. McKinsey estimates a 5-year healthspan extension adds $12T/year to global GDP. Conversely, explosive GDP growth funds the enormous R&D budgets required: population-scale deployment of age-reversing therapies may cost trillions. The timelines are roughly coincident (both P50 ~2048-2049), suggesting these gates may co-occur in the same economic transition.

Humanoid 10M households (P50 2035) <—> This gate: CORRELATES, WEAK. Partially substitutive: if aging halts, eldercare demand (a primary consumer humanoid use case) diminishes. But if aging does NOT halt in the near term, the growing 65+ population drives humanoid demand. The interaction is directionally ambiguous on net — weak correlation with sign depending on timing.

AI tutor K-8 parity (P50 2031) <—> This gate: CORRELATES, WEAK. If aging halts, career spans extend to 100+ years, making lifelong reskilling essential. AI tutors become the infrastructure for perpetual education. The longer the lifespan, the higher the ROI on every education investment. Weak but directionally positive.

Cell meat beef parity (P50 2036) <—> This gate: CORRELATES, WEAK. Caloric restriction and dietary optimization are among the most robust lifespan-extension interventions. Cultured meat at price parity enables precision nutrition at scale. Indirect but complementary.

Sources

  1. Longevity Startup Funding Trends — Crunchbase
  2. Top Longevity Startups by Fundraising 2026 — New Market Pitch
  3. Longevity Funding Landscape 2026 — AltStreet
  4. Life Biosciences FDA IND Clearance for ER-100 — BioSpace
  5. FDA go-ahead to test cellular rejuvenation in humans — Nature Biotechnology
  6. First human test of rejuvenation method — MIT Technology Review
  7. Retro Biosciences Alzheimer’s trial — WebProNews
  8. Retro Biosciences $1.8B valuation — STAT News
  9. Calico IL-11 antibody 9MW3811 deal — Longevity Technology
  10. IL-11 inhibition extends mammalian lifespan — Nature (2024)
  11. Insilico Medicine ISM001-055 Phase IIa — GEN
  12. Insilico Longevity Board announcement — PRNewswire
  13. PEARL Trial rapamycin results — Aging journal
  14. PEARL Trial analysis — AgelessRx
  15. TAME Trial status — AFAR
  16. Senolytics decrease senescent cells in humans — Mayo Clinic
  17. Rapamycin + trametinib 30% lifespan extension — Nature Aging
  18. Combination therapy lifespan extension — ScienceDaily
  19. Epigenetic clocks advancing toward clinical use — Lancet eBioMedicine
  20. Epigenetic clocks clinical validation — PMC
  21. Geroscience regulatory environments — PMC
  22. Geroscience in 2025 expert roundup — Lifespan.io
  23. From promise to practice: gerotherapeutics barriers — PMC
  24. Loyal LOY-002 FDA safety clearance — Yahoo Finance
  25. TRIAD trial design — GeroScience/Springer
  26. AI drug discovery reshaping longevity medicine — MedCity News
  27. Small molecule drug discovery for longevity — Pauling.AI
  28. Retro Biosciences + OpenAI partnership — Fortune
  29. Oldest living people — LongeviQuest
  30. Metaculus LEV prediction — Metaculus
  31. David Sinclair age-reversing pill prediction — NAD.com
  32. Sinclair at WGS 2026 — World Government Summit
  33. Aubrey de Grey longevity predictions — NMN.com
  34. Expert on super aging, anti-aging science and grift — NPR
  35. Altos Labs mesenchymal drift research — GEN
  36. Altos Labs becoming less stealthy — Fight Aging
  37. Remaining challenges in partial reprogramming — Fight Aging
  38. NAD+ precursors clinical evidence — SciExplor
  39. NMN vs NR vs NAM head-to-head trial — NMN.com
  40. Gene therapy for aging review — ScienceDirect (2025)
  41. Calico goes it alone after AbbVie split — Nature
  42. Longevity market funding trends 2022-2026 — New Market Pitch
Full markdown source (frontmatter + body) ▾
raw .md
View / download ↗ 
---
title: FDA or equivalent authority approves a drug (or therapy) that halts or reverses biological aging in humans
status: draft
dimensions: ["healthcare","labor","family","housing"]
horizon: long
trigger: The FDA, EMA, or another major regulatory authority (PMDA, NMPA) grants marketing approval — full or accelerated — to a drug or biological therapy whose labeled indication explicitly includes halting or reversing biological aging (as measured by a validated biomarker such as epigenetic age, DunedinPACE, or a composite aging endpoint), or whose Phase III/pivotal trial demonstrated statistically significant reduction in all-cause mortality or multi-morbidity incidence attributable to aging biology rather than a single disease.
timeline: {"p10":2037,"p50":2048,"p90":2072}
confidence: low
sub_gates: [{"slug":"fda-aging-indication-pathway","p50":2033,"why":"FDA or EMA formally establishes a regulatory pathway that recognizes aging (or a composite aging endpoint like multi-morbidity delay) as an approvable indication. The TAME trial design and PROSPR framework are prototypes but neither has yet yielded a licensed endpoint. Geroscience guidance documents are in draft; full pathway requires at least one completed aging-as-endpoint trial. P50 2033 assumes TAME or equivalent trial completes and catalyzes formal guidance."},{"slug":"first-senolytic-age-related-approval","p50":2035,"why":"First senolytic drug (dasatinib+quercetin combination, or next-gen like Calico's IL-11 antibody 9MW3811) approved for an age-related disease such as idiopathic pulmonary fibrosis, osteoarthritis, or diabetic kidney disease — not 'aging' per se, but paving the regulatory road. Calico's 9MW3811 completed Phase I (2025), extended mouse lifespan 22-25%; Phase II/III likely 2027-2032. Unity Biotechnology collapsed (2025), but pipeline assets may be acquired."},{"slug":"partial-reprogramming-safe-humans","p50":2034,"why":"Partial epigenetic reprogramming (OSK factors) demonstrated safe and effective in human tissue in a Phase II trial. Life Biosciences' ER-100 received FDA IND clearance January 28, 2026 for optic neuropathies — the first-ever human trial of cellular reprogramming. Phase I results expected ~2028; Phase II by ~2030-2032. Cancer/teratoma risk is the binding safety constraint. Altos Labs reportedly began early human testing August 2025 in kidney/heart/liver rejuvenation."},{"slug":"epigenetic-clock-validated-endpoint","p50":2032,"why":"An epigenetic clock (GrimAge, DunedinPACE, or successor) achieves formal regulatory validation as a surrogate endpoint for aging trials. Currently no clock has regulatory validation. DunedinPACE predicts mortality better than any clinical composite, but correlation-vs-causation gap remains. Lancet eBioMedicine 2026 review confirms clocks are 'advancing toward clinical use' but not there yet."},{"slug":"longevity-escape-velocity","p50":2057,"why":"Sustained life expectancy increase of >=1 year per year in any OECD country. Metaculus community median: June 2053 (143 forecasters). Requires not just one drug but a combinatorial therapy stack addressing multiple hallmarks of aging simultaneously. The rapamycin+trametinib combination (30% mouse lifespan extension, Nature Aging 2025) is the strongest single signal, but translating combinatorial geroprotection to humans adds 15-25 years of clinical development."},{"slug":"life-expectancy-100-oecd","p50":2065,"why":"Average life expectancy at birth crosses 100 in any OECD country. Current highest: Monaco 86.5, Japan 84.8, South Korea 84.4. Requires ~15-year gain from current peak. Historical rate of improvement is ~2.5 years/decade in top countries. Without breakthrough therapies, this doesn't happen until 2090+; with successful geroprotection deployment, P50 ~2065."}]
history: [{"date":"2026-05-27T00:00:00.000Z","p10":2037,"p50":2048,"p90":2072,"why":"Initial estimate from initial research."}]
cross_gate: [{"other":"ai-agent-30pct-knowledge-work","relation":"enables","strength":"strong","note":"AI agents autonomously handling 30%+ of knowledge work (P50 2029) directly accelerates drug discovery timelines. Retro Biosciences + OpenAI partnership already made reprogramming 50x more efficient (August 2025). Insilico Medicine's ISM001-055 is the first AI-discovered drug in Phase IIa. 173+ AI-discovered programs in clinical development as of 2026 with 80-90% Phase I success rates. AI compresses the 10-15 year drug development cycle by 3-5 years, pulling this gate's P10 materially forward."},{"other":"global-economy-explosive-growth","relation":"correlates","strength":"medium","note":"If aging is halted, the productive labor force expands indefinitely — no retirement wave, no dependency ratio crisis, human capital compounds over centuries rather than decades. This is the single strongest long-run GDP growth lever: McKinsey (2024) estimates that a 5-year healthspan extension adds $12T/year to global GDP. Conversely, explosive GDP growth funds the enormous R&D required for aging therapies (longevity biotech has attracted >$13B in VC funding but needs 10-100x more for population-scale deployment)."},{"other":"humanoid-10m-households","relation":"correlates","strength":"weak","note":"If aging is halted, eldercare demand (the primary consumer humanoid use case) is reduced, potentially slowing the demand curve for household humanoids. Conversely, if aging is NOT halted, the growing elderly population drives humanoid demand. The interaction is substitutive on the care dimension but complementary on the labor dimension (longer-lived humans + humanoids = larger total labor pool)."},{"other":"ai-tutor-k8-parity-20mo","relation":"correlates","strength":"weak","note":"If aging halts, lifelong learning becomes essential — career spans of 100+ years require constant reskilling. AI tutors at K-8 parity (P50 2031) become the infrastructure for perpetual education. The interaction strengthens over time: longer lives increase the ROI of every education investment."},{"other":"cell-meat-beef-parity","relation":"correlates","strength":"weak","note":"Nutrition science intersects longevity: caloric restriction remains the most robust lifespan-extension intervention across species. Cultured meat at price parity enables precision nutrition at scale — optimized protein without the inflammatory and carcinogenic profiles of conventional meat. Weak but directionally positive."},{"other":"brain-in-vat-body-replacement","relation":"substitutes","strength":"medium","note":"Both target life-extension via opposite mechanisms (preserve biology vs replace biology). If aging is halted (P50 2048), demand for full-body replacement collapses to a narrow niche of catastrophic-injury patients. Aging-halt converges 27+ years earlier and is likely the dominant longevity path; body-replacement is the brute-force fallback."}]
key_dependencies: [{"factor":"FDA aging-as-indication regulatory pathway","kind":"regulation","direction":"accelerates","linked_gate":null,"impact":"Without formal FDA/EMA recognition of aging as an approvable indication, the gate trigger cannot technically be met regardless of clinical evidence; establishment of this pathway (P50 2033) is the single most binding non-scientific prerequisite."},{"factor":"AI agents accelerating drug discovery","kind":"gate","direction":"accelerates","linked_gate":"ai-agent-30pct-knowledge-work","impact":"AI handling 30%+ of knowledge work by 2028 compresses the drug discovery cycle by 3-5 years and shifts this gate's P10 from 2040 to 2037, making it the strongest identified accelerant."},{"factor":"Partial reprogramming cancer safety signals","kind":"capability","direction":"delays","linked_gate":null,"impact":"A single teratoma or oncogenic event in the ER-100 or equivalent Phase I/II trial could set the entire reprogramming field back a decade, directly delaying the most promising therapeutic pathway."},{"factor":"Epigenetic clock validated as surrogate endpoint","kind":"data","direction":"accelerates","linked_gate":null,"impact":"Formal regulatory validation of DunedinPACE or GrimAge as a surrogate endpoint (P50 2032) is a prerequisite for any aging-specific pivotal trial; without it, multi-year mortality trials become the only option, adding 10-15 years to timelines."},{"factor":"Mouse-to-human translation failure","kind":"capability","direction":"delays","linked_gate":null,"impact":"If the 30% lifespan extension from rapamycin+trametinib in mice fails to translate to humans — as caloric restriction largely did in primates — the core pharmacological pipeline collapses and P90 extends well beyond 2072."},{"factor":"Explosive global economic growth","kind":"gate","direction":"both","linked_gate":"global-economy-explosive-growth","impact":"Explosive GDP growth funds the trillion-dollar R&D and deployment costs required for population-scale geroprotection, while aging-halt itself is the single strongest long-run GDP lever (McKinsey: 5-year healthspan extension adds $12T/year); the two gates are mutually reinforcing and roughly co-timed (both P50 ~2048-2049)."},{"factor":"Longevity biotech funding sustainability","kind":"market","direction":"both","linked_gate":null,"impact":"The sector has attracted $13B+ with zero approved products; accumulation of high-profile failures (Unity collapse, Calico ALS failure) could trigger investor retreat before science matures, while success in early sub-gates (dog longevity approval, first senolytic approval) could catalyze a funding surge that accelerates all subsequent timelines."}]
external_calibration: {"metaculus":"https://www.metaculus.com/questions/6592/when-will-a-country-reach-escape-velocity/","manifold":null,"expert_consensus":"David Sinclair (Harvard, WGS 2026): age-reversing pill available within 10 years (by ~2036), modern healthcare 'outdated' in 10-20 years. Aubrey de Grey (LEV Foundation): 50% chance of extending human lifespan by 20 years in next 12-15 years (by ~2038-2041); humans alive today will not die of age-related causes. Peter Fedichev (Gero): human aging is mostly stochastic and likely irreversible with foreseeable means — deep skeptic. Eric Topol: skeptical of anti-aging industry hype; emphasizes exercise, sleep, social connection over pharmacological approaches. Metaculus community: LEV median June 2053 (143 forecasters); 25+ year lifespan increase discovery by 2067 at ~55% probability. Conservative gerontology consensus: first disease-specific geroprotector approval 2030s; aging-as-indication approval 2040s-2050s; population-scale deployment 2050s-2060s. Optimist-pessimist spread is ~30 years (2035-2065), reflecting genuine scientific uncertainty about whether aging is a solvable engineering problem or an irreducible biological constraint."}
last_updated: "2026-05-27T00:00:00.000Z"
sources_count: 42
---

## TL;DR

This gate asks when a major regulatory authority will approve a therapy that explicitly halts or reverses biological aging — not just treats one age-related disease, but targets the aging process itself. **P50: 2048, P10: 2037, P90: 2072.** The field is at an inflection point in May 2026: the first-ever human trial of partial epigenetic reprogramming (Life Biosciences' ER-100, FDA IND cleared January 2026) is underway; Calico's IL-11 antibody (22-25% mouse lifespan extension) completed Phase I; rapamycin+trametinib combination showed 30% mouse lifespan extension (Nature Aging, May 2025); and over $13 billion in venture capital has flooded longevity biotech. But the gap between "extends mouse lifespan" and "FDA-approved age-freezing drug" is enormous: no regulatory authority recognizes aging as an approvable indication, no epigenetic clock is validated as a surrogate endpoint, and the most advanced human anti-aging trials are Phase I/II for disease-specific indications (not aging itself). The optimist case (P10 2037) requires AI-accelerated drug discovery to compress timelines by 5-10 years, the TAME trial or equivalent to establish aging-as-indication, and at least one geroprotector to show multi-morbidity reduction in a pivotal trial. The pessimist case (P90 2072) reflects the possibility that aging is too complex for a single drug, regulatory frameworks remain disease-specific for decades, or safety signals (cancer from reprogramming, immunosuppression from rapamycin) constrain deployment. The central estimate (P50 2048) assumes the regulatory pathway opens in the early 2030s, first disease-specific geroprotector approvals come in the mid-2030s, and the accumulated clinical evidence eventually supports an aging-specific indication by the late 2040s.

## Current state (as of 2026-05-27)

**Funding landscape:** Longevity biotech has attracted over $13 billion in cumulative venture funding. 2024-2025 saw a sharp rebound to ~$8.5B annually, with cellular reprogramming capturing 50% of all funding ($1.33B across 6 deals). Top-funded companies: Retro Biosciences ($1.2B, valued at $1.8B as of May 2026), Altos Labs ($3B, Bezos/Milner-backed), NewLimit ($280M, Brian Armstrong), Calico (>$2.5B from Alphabet cumulative). Big pharma entered in 2025: Eli Lilly invested in NewLimit; AbbVie Ventures led Oisin Biotechnologies' Series A (though AbbVie terminated its Calico collaboration in November 2025 after a Phase II/III ALS trial failure). Unity Biotechnology, once valued at $700M+, is no longer operating — a cautionary tale for the sector [1][2][3].

**Most advanced clinical programs (human trials):**

- **Life Biosciences ER-100** — First-ever human trial of partial epigenetic reprogramming. FDA IND cleared January 28, 2026. Phase I initiated Q1 2026 for optic neuropathies (glaucoma, NAION). Uses OSK Yamanaka factors (excluding c-Myc to reduce cancer risk). Co-founded by David Sinclair. If successful, provides proof-of-concept for cellular rejuvenation in humans [4][5][6].
- **Retro Biosciences RTR242** — Phase I trial in Australia (8 patients dosed December 2025) for Alzheimer's disease via enhanced cellular waste clearance. CEO Joe Betts-LaCroix reported "super good" progress with no dose-limiting toxicities; data expected August 2026 [7][8].
- **Calico 9MW3811 (anti-IL-11)** — Licensed from Mabwell for $25M upfront + $571M milestones (June 2025). Completed Phase I in Australia and China with favorable safety and >1-month half-life. Extended mouse lifespan 22-25% by reducing cancer, fibrosis, and chronic inflammation. Phase II planning underway [9][10].
- **Insilico Medicine ISM001-055 (rentosertib)** — First AI-discovered drug with anti-aging properties. Phase IIa trial (60 patients, US) with primary completion projected February 2026. Showed senomorphic properties — suppresses cellular senescence and SASP [11][12].
- **PEARL Trial (rapamycin)** — 48-week human RCT results published April 2025. Low-dose intermittent rapamycin is safe in healthy aging adults; improved lean tissue mass and pain in women (5mg group). However, relied on self-reporting and provided no direct evidence of lifespan extension [13][14].
- **TAME Trial (metformin)** — Still not launched as of 2026 due to persistent funding shortfalls. Aims to recruit 3,000 adults aged 65-80 for a 6-year trial of metformin to delay multimorbidity. May be overtaken by events [15].
- **Dasatinib+Quercetin senolytics** — Pilot human trials in diabetic kidney disease, Alzheimer's risk, psychiatric disorders. Reduced senescent cells and inflammation in DKD patients. Still early-phase with small cohorts [16].

**Animal model records:** The rapamycin+trametinib combination (Nature Aging, May 2025) achieved ~30% median lifespan extension in mice — the largest pharmacological effect from a defined combination to date. Rapamycin alone: 15-20%. Trametinib alone: 5-10%. Anti-IL-11 antibody: 22-25%. Aubrey de Grey's combination-of-four interventions in middle-aged mice showed additive effects; he plans an eight-intervention combination next [17][18].

**Epigenetic clocks and biomarkers:** GrimAge, DunedinPACE, and PhenoAge are the most clinically useful clocks in 2026. DunedinPACE measures rate-of-aging rather than static biological age and outperforms telomere length in mortality prediction. However, no epigenetic clock has achieved formal regulatory validation as a surrogate endpoint. The correlation-vs-causation gap remains open: it is unclear whether methylation changes drive or merely accompany aging [19][20].

**Regulatory environment:** No regulatory authority (FDA, EMA, PMDA, NMPA) currently recognizes aging as an approvable indication. The FDA's geroscience guidance encourages functional measures (walking speed, fall rates, hospitalizations) rather than biomarker-only endpoints. The PROSPR program aims to develop novel clinical trial designs for gerotherapeutics but remains pre-regulatory. The WHO's ICD-11 includes code MG2A ("Old age") but this is not equivalent to recognizing aging as a treatable disease. The field's regulatory strategy is to first win disease-specific approvals (IPF, DKD, osteoarthritis) that demonstrably target aging biology, then use accumulated evidence to argue for an aging indication [21][22][23].

**Dog longevity as leading indicator:** Loyal's LOY-002 has cleared 2 of 3 FDA-CVM technical sections (safety + reasonable expectation of effectiveness). If manufacturing review passes, conditional approval could come late 2026 or 2027 — making it the first drug approved to extend lifespan in any species. The TRIAD trial (rapamycin in ~580 dogs) is underway via the Dog Aging Project [24][25].

**AI acceleration:** 173+ AI-discovered programs are in clinical development (94 Phase I, 56 Phase II, 15 Phase III). AI-discovered compounds show 80-90% Phase I success rates vs. historical 40-65%. Retro + OpenAI partnership made reprogramming 50x more efficient. Insilico Medicine launched the industry's first Longevity Board (April 2026) for AI-enabled aging research oversight. Alphabet invests $50B in AI drug discovery via DeepMind, Isomorphic, and Calico [26][27][28].

**Supercentenarian context:** The oldest verified living person is Ethel Caterham (UK, born August 1909, age 116). The all-time record remains Jeanne Calment at 122 years 164 days. There are 269 validated living supercentenarians. The verified-lifespan ceiling has not meaningfully moved in 30 years — a signal that without intervention, human maximum lifespan may be biologically bounded [29].

## Key uncertainties

1. **Is aging a solvable engineering problem or an irreducible biological constraint?** Aubrey de Grey says engineering problem (SENS framework). Peter Fedichev says human aging is mostly stochastic and likely irreversible. This is the foundational uncertainty. If Fedichev is right, this gate may never pass. If de Grey is right, P10 could be aggressive.

2. **Will the FDA (or any regulator) create an aging-as-indication pathway?** Without this, therapies must be approved disease-by-disease (rapamycin for IPF, senolytics for DKD, etc.), and the gate trigger — approval of an "age-freezing drug" — cannot technically be met. The TAME trial was designed to force this regulatory conversation, but it remains unfunded after 8+ years.

3. **Cancer risk from partial reprogramming.** Yamanaka factors are potent oncogenes. Life Biosciences excluded c-Myc, but OCT4 and SOX2 are also associated with tumorigenesis. If Phase I/II safety signals emerge, the entire reprogramming field could be set back by a decade.

4. **Translation gap: mouse-to-human.** The 30% lifespan extension from rapamycin+trametinib in mice is extraordinary, but mouse-to-human translation in aging has historically been poor. Caloric restriction extends mouse lifespan by 30-40% but shows modest effects in primates. The species scaling problem is the most understudied bottleneck.

5. **AI-driven acceleration magnitude.** If AI compresses drug discovery from 10-15 years to 3-5 years (the optimist case), the P10 could be as early as 2035. If AI helps mainly with target identification but not clinical trials (which are bottlenecked by biology, not computation), the acceleration is modest.

6. **Combination therapy complexity.** Aging involves 12+ hallmarks (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, dysbiosis). A single drug targeting one hallmark may be insufficient. A validated combinatorial protocol requires exponentially more clinical testing.

7. **Public acceptance and access.** Even if approved, an age-freezing therapy could face political backlash (inequality concerns, population growth, pension system collapse) that limits deployment. Some jurisdictions may refuse to cover or even approve such therapies.

8. **Funding sustainability.** The longevity biotech sector has attracted >$13B but has produced zero approved products. If high-profile failures (Unity Biotechnology's collapse, Calico's ALS drug failure) accumulate, investor patience may wane before the science matures.

## Sub-gate deep dives

### FDA aging-as-indication pathway (P50: 2033)

The single most important regulatory prerequisite. Today, the FDA cannot approve a drug "for aging" because aging is not classified as a disease. The closest precedent is the TAME trial design, which proposed measuring time-to-first-occurrence of any age-related chronic disease (cardiovascular, cancer, dementia, mobility decline, cognitive decline, death) as a composite endpoint. This design was reviewed and accepted by the FDA as a valid trial framework, but the trial itself remains unfunded after 8+ years of effort.

The PROSPR program (American Federation for Aging Research) is developing novel clinical trial designs, real-world resilience metrics, and biomarker strategies for gerotherapeutics. If any of the current Phase I/II trials (ER-100, RTR242, 9MW3811) produce strong enough signals, they could catalyze FDA action. The geroscience community expects regulatory clarity by the early 2030s, with P50 2033 reflecting the likely timeline for completing a pivotal aging-endpoint trial + FDA guidance finalization.

### First senolytic approved for age-related disease (P50: 2035)

Senolytics — drugs that clear senescent cells — are the most conceptually straightforward anti-aging approach and have the most human safety data (dasatinib is FDA-approved for leukemia; quercetin is a dietary supplement). The combination has shown senescent cell clearance in DKD patients. However, the path to approval for an age-related indication requires large Phase III trials, which are expensive and slow. Calico's 9MW3811 (anti-IL-11) is a stronger candidate: it completed Phase I, showed dramatic mouse lifespan extension, has a well-characterized mechanism, and Calico has deep pockets ($571M in milestones committed). P50 2035 assumes Phase II (2027-2030), Phase III (2030-2034), and FDA review (2034-2035).

### Partial reprogramming safe in humans (P50: 2034)

Life Biosciences' ER-100 Phase I (optic neuropathies, initiated Q1 2026) is the critical test. If safety data are clean by ~2028, Phase II could begin 2029-2030. Altos Labs is reportedly in early human testing as of August 2025. Turn Biotechnologies' ERA platform is in late preclinical for dermatology and immunology. The cancer risk question is paramount: even a single teratoma in a clinical trial would be a major setback. P50 2034 assumes Phase I safety established by 2028, Phase II efficacy in a tissue-specific indication by 2032, and broader safety confidence by 2034.

### Epigenetic clock validated as regulatory endpoint (P50: 2032)

DunedinPACE and GrimAge are the leading candidates. Validation requires demonstrating that a change in epigenetic age predicts a change in hard clinical outcomes (mortality, multi-morbidity) in a prospective trial. The Lancet eBioMedicine review (2026) confirms clocks are "advancing toward clinical use" but notes the correlation-vs-causation gap. P50 2032 assumes at least one completed RCT using an epigenetic clock as a co-primary endpoint by 2030, with 2 years for regulatory review and formal guidance.

### Longevity escape velocity (P50: 2057)

LEV — sustained life expectancy increase of >=1 year per year — is the downstream consequence of this gate, not a prerequisite. Metaculus community median: June 2053 (143 forecasters). Requires not just one approved drug but a combinatorial therapy stack deployed at population scale. P50 2057 reflects the lag between first approval (P50 2048 for this gate) and population-scale deployment + accumulated evidence that the therapy actually extends life expectancy at the population level.

### Life expectancy crosses 100 in OECD country (P50: 2065)

Current highest life expectancy: Monaco 86.5 years. Historical improvement rate: ~2.5 years/decade in top countries. Without breakthrough therapies, 100 is not reachable until 2090+. With successful geroprotector deployment starting in the 2040s-2050s, the curve accelerates. P50 2065 assumes therapies approved in the late 2040s take 15-20 years to bend the population curve enough.

## Cross-gate interactions

**AI agent 30% knowledge work (P50 2029) --> This gate: ENABLES, STRONG.** AI is already the leading accelerant for longevity drug discovery. The Retro+OpenAI partnership made cellular reprogramming 50x more efficient. Insilico Medicine's ISM001-055 went from AI target discovery to Phase IIa in under 4 years — a timeline that would have been 8-12 years conventionally. If AI agents handle 30%+ of knowledge work by 2029, the drug discovery cycle compresses further: literature synthesis, target identification, molecular design, clinical trial optimization, and regulatory submission preparation are all knowledge-work tasks. This is the most important cross-gate interaction: it shifts the P10 of this gate from 2040 to 2037.

**Global economy explosive growth (P50 2049) <--> This gate: CORRELATES, MEDIUM.** Bidirectional interaction. If aging is halted, the dependency ratio inverts (no retirement wave), human capital compounds over centuries, and GDP growth accelerates — potentially contributing to explosive growth. McKinsey estimates a 5-year healthspan extension adds $12T/year to global GDP. Conversely, explosive GDP growth funds the enormous R&D budgets required: population-scale deployment of age-reversing therapies may cost trillions. The timelines are roughly coincident (both P50 ~2048-2049), suggesting these gates may co-occur in the same economic transition.

**Humanoid 10M households (P50 2035) <--> This gate: CORRELATES, WEAK.** Partially substitutive: if aging halts, eldercare demand (a primary consumer humanoid use case) diminishes. But if aging does NOT halt in the near term, the growing 65+ population drives humanoid demand. The interaction is directionally ambiguous on net — weak correlation with sign depending on timing.

**AI tutor K-8 parity (P50 2031) <--> This gate: CORRELATES, WEAK.** If aging halts, career spans extend to 100+ years, making lifelong reskilling essential. AI tutors become the infrastructure for perpetual education. The longer the lifespan, the higher the ROI on every education investment. Weak but directionally positive.

**Cell meat beef parity (P50 2036) <--> This gate: CORRELATES, WEAK.** Caloric restriction and dietary optimization are among the most robust lifespan-extension interventions. Cultured meat at price parity enables precision nutrition at scale. Indirect but complementary.

## Sources

1. [Longevity Startup Funding Trends — Crunchbase](https://news.crunchbase.com/venture/longevity-startup-funding-2025-newlimit-data/)
2. [Top Longevity Startups by Fundraising 2026 — New Market Pitch](https://newmarketpitch.com/blogs/news/longevity-top-startups-fundraising)
3. [Longevity Funding Landscape 2026 — AltStreet](https://altstreet.investments/blog/longevity-funding-landscape-2026-geroscience-investment)
4. [Life Biosciences FDA IND Clearance for ER-100 — BioSpace](https://www.biospace.com/press-releases/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies)
5. [FDA go-ahead to test cellular rejuvenation in humans — Nature Biotechnology](https://www.nature.com/articles/s41587-026-03037-z)
6. [First human test of rejuvenation method — MIT Technology Review](https://www.technologyreview.com/2026/01/27/1131796/the-first-human-test-of-a-rejuvenation-method-will-begin-shortly/)
7. [Retro Biosciences Alzheimer's trial — WebProNews](https://www.webpronews.com/sam-altman-backed-retro-biosciences-starts-alzheimers-reversal-trial/)
8. [Retro Biosciences $1.8B valuation — STAT News](https://www.statnews.com/2026/05/22/retro-biosciences-longevity-valuation/)
9. [Calico IL-11 antibody 9MW3811 deal — Longevity Technology](https://longevity.technology/news/calico-inks-596m-deal-for-drugs-targeting-longevity-linked-cytokine/)
10. [IL-11 inhibition extends mammalian lifespan — Nature (2024)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291288/)
11. [Insilico Medicine ISM001-055 Phase IIa — GEN](https://www.genengnews.com/topics/artificial-intelligence/insilico-eyes-q4-start-for-late-stage-trials-of-ipf-candidate/)
12. [Insilico Longevity Board announcement — PRNewswire](https://www.prnewswire.com/news-releases/insilico-medicine-announces-industrys-first-longevity-board-to-accelerate-ai-driven-aging-research-for-drug-discovery-302748726.html)
13. [PEARL Trial rapamycin results — Aging journal](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074816/)
14. [PEARL Trial analysis — AgelessRx](https://agelessrx.com/results-of-the-pearl-trial/)
15. [TAME Trial status — AFAR](https://www.afar.org/tame-trial)
16. [Senolytics decrease senescent cells in humans — Mayo Clinic](https://mayoclinic.elsevierpure.com/en/publications/senolytics-decrease-senescent-cells-in-humans-preliminary-report-/)
17. [Rapamycin + trametinib 30% lifespan extension — Nature Aging](https://www.nature.com/articles/s43587-025-00876-4)
18. [Combination therapy lifespan extension — ScienceDaily](https://www.sciencedaily.com/releases/2025/05/250528132123.htm)
19. [Epigenetic clocks advancing toward clinical use — Lancet eBioMedicine](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00056-3/fulltext)
20. [Epigenetic clocks clinical validation — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12905613/)
21. [Geroscience regulatory environments — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12310402/)
22. [Geroscience in 2025 expert roundup — Lifespan.io](https://lifespan.io/geroscience-in-2025-the-expert-roundup/)
23. [From promise to practice: gerotherapeutics barriers — PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486172/)
24. [Loyal LOY-002 FDA safety clearance — Yahoo Finance](https://finance.yahoo.com/news/loyal-receives-fda-acceptance-safety-140000887.html)
25. [TRIAD trial design — GeroScience/Springer](https://link.springer.com/article/10.1007/s11357-024-01484-7)
26. [AI drug discovery reshaping longevity medicine — MedCity News](https://medcitynews.com/2026/04/ai-drug-discovery-is-reshaping-longevity-medicine-is-your-practice-ready/)
27. [Small molecule drug discovery for longevity — Pauling.AI](https://blog.pauling.ai/p/small-molecule-drug-discovery-for)
28. [Retro Biosciences + OpenAI partnership — Fortune](https://fortune.com/2025/01/24/sam-altman-ai-biotech-1-billion-funding-extend-human-lifespan/)
29. [Oldest living people — LongeviQuest](https://longeviquest.com/)
30. [Metaculus LEV prediction — Metaculus](https://www.metaculus.com/questions/6592/when-will-a-country-reach-escape-velocity/)
31. [David Sinclair age-reversing pill prediction — NAD.com](https://www.nad.com/news/anti-aging-breakthrough-dr-david-sinclair-predicts-age-reversing-pill-by-2035)
32. [Sinclair at WGS 2026 — World Government Summit](https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026)
33. [Aubrey de Grey longevity predictions — NMN.com](https://www.nmn.com/news/aubrey-de-grey-on-the-future-of-longevity-and-aging-research)
34. [Expert on super aging, anti-aging science and grift — NPR](https://www.npr.org/2026/05/01/nx-s1-5770418/expert-super-aging-science-anti-aging)
35. [Altos Labs mesenchymal drift research — GEN](https://www.genengnews.com/insights/esgct-2025-altos-labs-scientific-founder-targets-mesenchymal-drift-in-efforts-to-combat-diseases-of-aging/)
36. [Altos Labs becoming less stealthy — Fight Aging](https://www.fightaging.org/archives/2026/05/partial-reprogramming-concern-altos-labs-is-becoming-less-stealthy/)
37. [Remaining challenges in partial reprogramming — Fight Aging](https://www.fightaging.org/archives/2026/04/remaining-challenges-in-the-development-of-partial-reprogramming-therapies/)
38. [NAD+ precursors clinical evidence — SciExplor](https://sciexplor.com/articles/Geromedicine.2025.0008)
39. [NMN vs NR vs NAM head-to-head trial — NMN.com](https://www.nmn.com/news/scientists-unveil-results-from-human-trial-directly-comparing-three-nad-precursors)
40. [Gene therapy for aging review — ScienceDirect (2025)](https://www.sciencedirect.com/science/article/abs/pii/S1568163726001364)
41. [Calico goes it alone after AbbVie split — Nature](https://www.nature.com/articles/d41573-025-00205-9)
42. [Longevity market funding trends 2022-2026 — New Market Pitch](https://newmarketpitch.com/blogs/news/longevity-funding-trends)